Ian D. Clough
Known title: DirectorCIK: 0001663177
Associated companies
Transaction History
| BCO | ▲ Buy | Grant | 157 | $0 | 10/1/2026 | View on chart |
| BCO | ▲ Buy | Grant | 167 | $0 | 7/1/2026 | View on chart |
| BCO | ▲ Buy | Option Exercise | 1,844 | $0 | 4/28/2026 | View on chart |
| BCO | ▲ Buy | Grant | 153 | $0 | 4/1/2026 | View on chart |
| BCO | ▲ Buy | Grant | 136 | $0 | 1/1/2026 | View on chart |
| BCO | ▲ Buy | Grant | 136 | $0 | 10/1/2025 | View on chart |
| BCO | ▲ Buy | Grant | 168 | $0 | 7/1/2025 | View on chart |
| BCO | ▲ Buy | Option Exercise | 1,705 | $0 | 5/2/2025 | View on chart |
| BCO | ▲ Buy | Grant | 130 | $0 | 4/1/2025 | View on chart |
| BCO | ▲ Buy | Grant | 157 | $0 | 1/1/2025 | View on chart |
| BCO | ▲ Buy | Grant | 126 | $0 | 10/1/2024 | View on chart |
| BCO | ▲ Buy | Grant | 142 | $0 | 7/1/2024 | View on chart |
| BCO | ▲ Buy | Option Exercise | 2,402 | — | 5/2/2024 | View on chart |
| BCO | ▲ Buy | Grant | 158 | $0 | 4/1/2024 | View on chart |
| BCO | ▲ Buy | Grant | 165 | $0 | 1/1/2024 | View on chart |
| BCO | ▲ Buy | Grant | 201 | $0 | 10/1/2023 | View on chart |
| BCO | ▲ Buy | Grant | 208 | $0 | 7/1/2023 | View on chart |
| BCO | ▲ Buy | Option Exercise | 2,652 | — | 5/5/2023 | View on chart |
| BCO | ▲ Buy | Grant | 209 | $0 | 4/1/2023 | View on chart |
| BCO | ▲ Buy | Grant | 261 | $0 | 1/1/2023 | View on chart |
| BCO | ▲ Buy | Grant | 289 | $0 | 10/3/2022 | View on chart |
| BCO | ▲ Buy | Grant | 230 | $0 | 7/1/2022 | View on chart |
| BCO | ▲ Buy | Option Exercise | 1,818 | — | 5/6/2022 | View on chart |
| BCO | ▲ Buy | Grant | 205 | $0 | 4/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Brink's Gets CMA Approval for NCR Atleos Deal Remedy
Brink's received acceptance in principle from the UK's CMA regarding a proposed remedy for its pending acquisition of NCR Atleos. The company also reported Q2 2026 results and confirmed that a potential sale of UK assets will not impact expected $200M in annual synergies. This regulatory progress is a key step in finalizing the transaction.
Brink's Gets CMA Approval for NCR Atleos Deal Remedy. Brink's received acceptance in principle from the UK's CMA regarding a proposed remedy for its pending acquisition of NCR Atleos. The company also reported Q2 2026 results and confirmed that a potential sale of UK assets will not impact expected $200M in annual synergies. This regulatory progress is a key step in finalizing the transaction.